Suspensions of antibiotics in self-emulsifying oils as a novel approach to formulate eye drops with substances which undergo hydrolysis in aqueous environment.


Journal

Drug delivery
ISSN: 1521-0464
Titre abrégé: Drug Deliv
Pays: England
ID NLM: 9417471

Informations de publication

Date de publication:
Dec 2024
Historique:
medline: 12 7 2024
pubmed: 12 7 2024
entrez: 11 7 2024
Statut: ppublish

Résumé

The aim of this study was to develop eye-drops with cefuroxime (CEF) sodium or vancomycin (VAN) hydrochloride, antibiotics that are instable in water. Anhydrous self-emulsifying oils (SEO) are proposed as a carrier and antibiotics are suspended. In the contact with tear fluid, the formulation should transform into emulsion, with fast dissolution of an antibiotic. CEF or VAN (5% w/w) was suspended in SEO carriers prepared by dissolving surfactants (Tween 20 or Span 80 5% w/w) in Miglyol, castor oil, or olive oil. Formulations with or without sodium citrate (2% w/w) were compared. Six-months or 1-year stability tests were carried out at 40 °C. The content of CEF and VAN was evaluated using HPLC and the potency of the antibiotic was assessed with agar diffusion method. In contact with water, drug particles suspended in SEO dissolved rapidly and o/w emulsion was formed. After 1-year at 40 °C, the content of degradation products was at most 0.5% in CEF and 4.0% in VAN formulations. The agar diffusion assay has shown that CEF and VAN loaded into SEO retained its potency against the sensitive microorganisms comparable to an aqueous solution. Therefore, SEO can be used as a novel carrier for the active substances which may not require improved solubility or absorption but need to be protected from moisture. This is a formulation that can be produced on industrial scale, with no limitation of stability or drug concentration.

Identifiants

pubmed: 38992340
doi: 10.1080/10717544.2024.2372279
doi:

Substances chimiques

Anti-Bacterial Agents 0
Emulsions 0
Ophthalmic Solutions 0
Castor Oil 8001-79-4
Cefuroxime O1R9FJ93ED
Vancomycin 6Q205EH1VU
Surface-Active Agents 0
Suspensions 0
Water 059QF0KO0R
Polysorbates 0
Olive Oil 0
Hexoses 0
sorbitan monooleate 06XEA2VD56
Drug Carriers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2372279

Auteurs

Katarzyna Krzeminska (K)

Department of Pharmaceutical Technology, Faculty of Pharmacy, Medical University of Gdansk, Gdansk, Poland.

Malgorzata Sznitowska (M)

Department of Pharmaceutical Technology, Faculty of Pharmacy, Medical University of Gdansk, Gdansk, Poland.

Magdalena Wroblewska (M)

Department of Pharmaceutical Technology, Faculty of Pharmacy, Medical University of Bialystok, Bialystok, Poland.

Eliza Wolska (E)

Department of Pharmaceutical Technology, Faculty of Pharmacy, Medical University of Gdansk, Gdansk, Poland.

Katarzyna Winnicka (K)

Department of Pharmaceutical Technology, Faculty of Pharmacy, Medical University of Bialystok, Bialystok, Poland.

Articles similaires

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male
Humans Arthroplasty, Replacement, Elbow Prosthesis-Related Infections Debridement Anti-Bacterial Agents
Animals Dietary Fiber Dextran Sulfate Mice Disease Models, Animal
Vancomycin Polyesters Anti-Bacterial Agents Models, Theoretical Drug Liberation

Classifications MeSH